These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31890857)

  • 1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.
    Stamate D; Kim M; Proitsi P; Westwood S; Baird A; Nevado-Holgado A; Hye A; Bos I; Vos SJB; Vandenberghe R; Teunissen CE; Kate MT; Scheltens P; Gabel S; Meersmans K; Blin O; Richardson J; De Roeck E; Engelborghs S; Sleegers K; Bordet R; Ramit L; Kettunen P; Tsolaki M; Verhey F; Alcolea D; Lléo A; Peyratout G; Tainta M; Johannsen P; Freund-Levi Y; Frölich L; Dobricic V; Frisoni GB; Molinuevo JL; Wallin A; Popp J; Martinez-Lage P; Bertram L; Blennow K; Zetterberg H; Streffer J; Visser PJ; Lovestone S; Legido-Quigley C
    Alzheimers Dement (N Y); 2019; 5():933-938. PubMed ID: 31890857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
    Kim M; Snowden S; Suvitaival T; Ali A; Merkler DJ; Ahmad T; Westwood S; Baird A; Proitsi P; Nevado-Holgado A; Hye A; Bos I; Vos S; Vandenberghe R; Teunissen C; Ten Kate M; Scheltens P; Gabel S; Meersmans K; Blin O; Richardson J; De Roeck E; Sleegers K; Bordet R; Rami L; Kettunen P; Tsolaki M; Verhey F; Sala I; Lléo A; Peyratout G; Tainta M; Johannsen P; Freund-Levi Y; Frölich L; Dobricic V; Engelborghs S; Frisoni GB; Molinuevo JL; Wallin A; Popp J; Martinez-Lage P; Bertram L; Barkhof F; Ashton N; Blennow K; Zetterberg H; Streffer J; Visser PJ; Lovestone S; Legido-Quigley C
    Alzheimers Dement; 2019 Jun; 15(6):817-827. PubMed ID: 31078433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
    Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
    Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset.
    Hong S; Prokopenko D; Dobricic V; Kilpert F; Bos I; Vos SJB; Tijms BM; Andreasson U; Blennow K; Vandenberghe R; Cleynen I; Gabel S; Schaeverbeke J; Scheltens P; Teunissen CE; Niemantsverdriet E; Engelborghs S; Frisoni G; Blin O; Richardson JC; Bordet R; Molinuevo JL; Rami L; ; Kettunen P; Wallin A; Lleó A; Sala I; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Dobson RJB; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Wittig M; Franke A; Tanzi RE; Visser PJ; Bertram L
    Transl Psychiatry; 2020 Nov; 10(1):403. PubMed ID: 33223526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics.
    Gaetani L; Bellomo G; Parnetti L; Blennow K; Zetterberg H; Di Filippo M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
    Huan T; Tran T; Zheng J; Sapkota S; MacDonald SW; Camicioli R; Dixon RA; Li L
    J Alzheimers Dis; 2018; 65(4):1401-1416. PubMed ID: 30175979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning based on metabolomics reveals potential targets and biomarkers for primary Sjogren's syndrome.
    Wang K; Li J; Meng D; Zhang Z; Liu S
    Front Mol Biosci; 2022; 9():913325. PubMed ID: 36133908
    [No Abstract]   [Full Text] [Related]  

  • 19. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
    Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [
    Westwood S; Baird AL; Hye A; Ashton NJ; Nevado-Holgado AJ; Anand SN; Liu B; Newby D; Bazenet C; Kiddle SJ; Ward M; Newton B; Desai K; Tan Hehir C; Zanette M; Galimberti D; Parnetti L; Lleó A; Baker S; Narayan VA; van der Flier WM; Scheltens P; Teunissen CE; Visser PJ; Lovestone S
    Front Aging Neurosci; 2018; 10():409. PubMed ID: 30618716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.